Bellerophon Therapeutics, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| ACADIAN ASSET MANAGEMENT LLC | 02/13/2024 | 199.60 K | $6.00 K | -47.91% | 1.63% |
| RAYMOND JAMES & ASSOCIATES | 01/16/2024 | 10.00 K | $370 | 0.00% | 0.08% |
| US BANCORP \DE\ | 02/09/2024 | 0 | $0 | -100.00% | 0.00% |
| WELLS FARGO & COMPANY/MN | 02/09/2024 | 0 | $0 | -100.00% | 0.00% |
| NORTHERN TRUST CORP | 02/13/2024 | 0 | $0 | -100.00% | 0.00% |
| STATE STREET CORP | 02/14/2024 | 0 | $0 | -100.00% | 0.00% |
| VANGUARD GROUP INC | 03/11/2024 | 0 | $0 | -100.00% | 0.00% |
| MORGAN STANLEY | 08/16/2024 | 0 | $0 | -100.00% | 0.00% |
| GROUP ONE TRADING, L.P. | 02/14/2024 | 0 | $0 | -100.00% | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC | 02/13/2024 | 0 | $0 | -100.00% | 0.00% |
| TWO SIGMA INVESTMENTS, LP | 02/14/2024 | 0 | $0 | -100.00% | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 02/13/2024 | 0 | $0 | -100.00% | 0.00% |
| BLACKROCK INC. | 02/13/2024 | 0 | $0 | -100.00% | 0.00% |
| CITADEL ADVISORS LLC | 02/14/2024 | 0 | $0 | -100.00% | 0.00% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 02/14/2024 | 0 | $0 | -100.00% | 0.00% |
| TWO SIGMA ADVISERS, LP | 02/14/2024 | 0 | $0 | -100.00% | 0.00% |
| TOWER RESEARCH CAPITAL LLC (TRC) | 02/13/2024 | 0 | $0 | -100.00% | 0.00% |
| ADVISOR GROUP HOLDINGS, INC. | 02/12/2024 | 0 | $0 | -100.00% | 0.00% |
| QUBE RESEARCH & TECHNOLOGIES LTD | 02/13/2024 | 0 | $0 | -100.00% | 0.00% |
| GPS WEALTH STRATEGIES GROUP, LLC | 01/12/2024 | 0 | $0 | -100.00% | 0.00% |
| GLOBAL WEALTH STRATEGIES & ASSOCIATES | 01/02/2024 | 0 | $0 | -100.00% | 0.00% |
| PFS PARTNERS, LLC | 01/29/2024 | 0 | $0 | -100.00% | 0.00% |
Bellerophon Therapeutics, Inc. institutional Ownership - FAQ's
During the previous two years, 2 institutional investors and hedge funds held shares of Bellerophon Therapeutics, Inc.. The most heavily invested institutionals were:
Telemetry Investments, L.L.C.: 44,000
Puissance Capital Management LP: 1.15 M
1.71% of Bellerophon Therapeutics, Inc. stock is owned by institutional investors.
Institutional investors have bought a total of 1.20 M shares in the last 24 months. This purchase volume represents approximately $11.98 K in transactions.